Defining bacillus Calmette-Guerin refractory superficial bladder tumors Journal Article


Authors: Herr, H. W.; Dalbagni, G.
Article Title: Defining bacillus Calmette-Guerin refractory superficial bladder tumors
Abstract: Purpose: We define bacillus Calmette-Guerin (BCG) refractory, high risk, superficial bladder cancer. Materials and Methods: A total of 93 patients received a 6-week induction course of BCG. They were evaluated for response after 3 and 6 months. Half of the patients received monthly maintenance BCG for 2 years and half did not. In both groups the initial responses to BCG at 3 and 6 months were correlated with subsequent tumor recurrence and progression. Results: Of the 93 cases 57% were negative for tumor at 3 months and 43% had residual tumor resected. At 6 months 80% of the patients were tumor-free and 20% had persistent or recurrent tumor. Maintenance BCG did not decrease tumor recurrence further than induction BCG. Subsequent tumor-free interval during 24 months of followup were best predicted by response to BCG after 6 months. Conclusions: A minimum treatment and followup time of 6 months is required to identify high risk, superficial bladder tumors as truly BCG refractory.
Keywords: treatment outcome; treatment failure; major clinical study; cancer recurrence; salvage therapy; cancer growth; cancer risk; follow up; bcg vaccine; drug resistance; drug resistance, neoplasm; bladder cancer; bladder tumor; urinary bladder neoplasms; time factors; disease progression; bladder neoplasms; adjuvants, immunologic; humans; human; priority journal; article
Journal Title: Journal of Urology
Volume: 169
Issue: 5
ISSN: 0022-5347
Publisher: Elsevier Science, Inc.  
Date Published: 2003-05-01
Start Page: 1706
End Page: 1708
Language: English
DOI: 10.1097/01.ju.0000062605.92268.c6
PUBMED: 12686813
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 12 September 2014 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Guido Dalbagni
    325 Dalbagni
  2. Harry W Herr
    594 Herr